Clinical Trial Update: Effect of SAR302503 on ECG Activity in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the effect of SAR302503 on ECG activity in patients with solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• SAR302503

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Neoplasm Malignant | Phase 1 | Status: COMPLETED